Señales en vivo de ABUS | Maximiza tus Ganancias con Getagraph.com

COMPRAR 118628 min ago

@ $2.78

Emitido: 13 feb 2024 @ 09:30

Retorno: -2.45%

Señal anterior: feb 12 - 09:32

Señal anterior: Vender

Retorno: -2.53 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States...

Stats
Volumen de hoy	683 613
Volumen promedio	1.39M
Capitalización de mercado	511.42M
EPS	$-0.120 ( 2024-05-02 )
Próxima fecha de ganancias	( $-0.110 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.16
ATR14	$0.00400 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Naftzger J. Christopher	Buy	380 500	Stock Option (Right to Buy)
2024-02-01	Naftzger J. Christopher	Buy	95 100	Common Shares
2024-02-01	Sims Karen	Buy	403 900	Stock Option (Right to Buy)
2024-02-01	Sims Karen	Buy	101 000	Common Shares
2024-02-02	Sims Karen	Sell	4 358	Common Shares

INSIDER POWER
90.40
Last 95 transactions
Buy: 35 682 262 \| Sell: 1 766 657

Volumen Correlación

Largo: -0.40 (neutral)

Corto: -0.82 (strong negative)

Signal:(37.047) Neutral

Arbutus Biopharma Corp Correlación

10 Correlaciones Más Positivas
GETVV	0.964
PPBT	0.935
SISI	0.934
DRTT	0.929
WATT	0.926
TPST	0.925
GMBL	0.925
GLMD	0.921
NCBS	0.921
CRTD	0.918

10 Correlaciones Más Negativas
PPSI	-0.942
SLAM	-0.941
GSHD	-0.937
GFGD	-0.937
GASS	-0.933
AAPL	-0.933
UFPI	-0.931
NECB	-0.931
VERA	-0.93
UFPT	-0.93

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arbutus Biopharma Corp Correlación - Moneda/Commodity

-0.54
( weak negative )

-0.53
( weak negative )

0.00
( neutral )

0.02
( neutral )

Arbutus Biopharma Corp Finanzas

Annual	2023
Ingresos:	$18.14M
Beneficio Bruto:	$16.74M (92.26 %)
EPS:	$-0.440

FY	2023
Ingresos:	$18.14M
Beneficio Bruto:	$16.74M (92.26 %)
EPS:	$-0.440

FY	2022
Ingresos:	$39.02M
Beneficio Bruto:	$37.59M (96.34 %)
EPS:	$-0.460

FY	2021
Ingresos:	$10.99M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.830

Financial Reports:

No articles found.

Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.